Description

Regorafenib CAS NO 835621-08-4 is a potent, orally active multi-kinase inhibitor belonging to the class of small molecule pharmaceuticals. This compound is of critical importance for its targeted therapeutic action in oncology research and development. It is primarily required by pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions engaged in the synthesis of novel drug formulations and advanced cancer treatment studies.

Application

• Pharmaceutical Active Ingredient (API): Serves as the core active pharmaceutical ingredient in the manufacture of finished dosage forms for targeted cancer therapy.
• Oncology Research: A key reference standard and investigational compound in preclinical and clinical studies for evaluating efficacy against various solid tumors.
• Biochemical Pathway Inhibition: Used in laboratory settings to study the inhibition of multiple kinase pathways involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment.
• Reference Standard for QC: Employed as a high-purity analytical reference standard in quality control laboratories for method development, validation, and assay calibration.
• Drug Discovery & Development: Integral to medicinal chemistry programs for structure-activity relationship (SAR) studies and the development of next-generation kinase inhibitors.
• Formulation Development: Utilized in R&D for developing stable and bioavailable oral formulations, such as tablets or capsules.

Basic Information

Product Name	Regorafenib
CAS No.	835621-08-4
Molecular Formula	C21H15ClF4N4O3
Molecular Weight	482.82 g/mol
Synonyms	Regorafenib; BAY 73-4506; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; Stivarga (Brand Name); Fluoro-Sorafenib; Multikinase inhibitor BAY 73-4506; UNII-24T2A1DOYB
EINECS	Contact for details

Quality Control

Our Regorafenib is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, residual solvent analysis, and identification by spectroscopic methods, to ensure it meets stringent specifications for pharmaceutical research. Certificates of Analysis (COA) documenting purity, identity, and impurity profiles are available upon request to support your regulatory and R&D needs.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15-25°C (59-77°F). Keep the container in a dry, cool, and well-ventilated area. For long-term storage under inert atmosphere, please contact our technical team for specific recommendations.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.